New Biotech and Healthcare Platform based on US-India Innovation Corridor

New Biotech and Healthcare Platform based on US-India Innovation Corridor

Creating a 3-pillar healthcare platform at the intersection of biotech, medical devices, and AI in healthcare.

New Biotech and Healthcare Platform based on US-India Innovation Corridor

Creating a 3-pillar healthcare platform at the intersection of biotech, medical devices, and AI in healthcare.

$120B+

$120B+

$120B+

$120B+

of Immuno-Inflammatory Opportunity

of Immuno-Inflammatory Opportunity

For nearly a decade, Vyome has invested millions of dollars to build a portfolio of immuno-inflammatory assets rooted in strong mechanistic science.

Today, that focus is delivering results, with multiple programs advancing toward 12–24 month catalysts that have the potential to create meaningful impact for patients and value for stakeholders.

For nearly a decade, Vyome has invested millions of dollars to build a portfolio of immuno-inflammatory assets rooted in strong mechanistic science.

Today, that focus is delivering results, with multiple programs advancing toward 12–24 month catalysts that have the potential to create meaningful impact for patients and value for stakeholders.

Three Pillars. One Vision.

Three Pillars. One Vision.

Our approach combines world-class science, medical talent, and capital efficiency across the US and India to unlock innovation and impact in healthcare.

Our approach combines world-class science, medical talent, and capital efficiency across the US and India to unlock innovation and impact in healthcare.

Biotech & Pharma

Developing clinical-stage therapies for underserved conditions, wit near-term catalysts.

Developing clinical-stage therapies for underserved conditions, wit near-term catalysts.

Medical Devices

Acquiring and scaling proven innovations across markets.

Acquiring and scaling proven innovations across markets.

AI in Healthcare

Harnessing data and intelligence to transform patient outcomes.

Harnessing data and intelligence to transform patient outcomes.

Advancing treatments in areas of urgent need and low innovation.

At Vyome, we focus on immuno-inflammatory diseases that lack effective treatments, designing therapies that restore balance and improve lives.

At Vyome, we focus on immuno-inflammatory diseases that lack effective treatments, designing therapies that restore balance and improve lives.

Explore our Pipeline

Malignant Fungating Wounds
Bringing dignity back to late-stage cancer care

Bringing dignity back to late-stage cancer care

Bringing dignity back to late-stage cancer care

VT1953 is the first targeted therapy for MFW. Reducing odor, pain, and inflammation through a dual mechanism.

- 75% reduction in malodor early efficacy analysis
- No approved drugs exist today
- Orphan designation potential

Uveitis
A safer and steroid sparing path for Uvetis

A safer and steroid sparing path for Uvetis

A safer and steroid sparing path for Uvetis

VT1908, our non-steroidal eye drop, matches steroid performance in preclinical models—without the risks.

- Targets IMPDH to block immune cell overactivity
- Designed for patients who can’t use steroids
- Efficient regulatory path for rare indication

Drug-Resistant Acne
Next-gen acne treatment for the antibiotic resistant inflammatory acne

Next-gen acne treatment for the antibiotic resistant inflammatory acne

Next-gen acne treatment for the antibiotic resistant inflammatory acne

VB1953 treats resistant P. acnes strains while calming inflammation. Offering hope for millions failed by existing topicals.

- Dual action: DNA gyrase + TLR-MD2 inhibition
- Proven efficacy in clindamycin non-responders
- Best-in-class safety and proven efficacy profile in more than 550 patients including a large Phase 2 study

Positioned For Growth

Positioned For Growth

Immuno-inflammatory diseases alone represent a $120B+ market growing rapidly.

Immuno-inflammatory diseases alone represent a $120B+ market growing rapidly.

Patients with rare or resistant conditions are still underserved.

Patients with rare or resistant conditions are still underserved.

US–India innovation corridor is at a historic inflection point.

US–India innovation corridor is at a historic inflection point.

Vyome’s clean capital structure and platform model position us to deliver outsized impact.

Vyome’s clean capital structure and platform model position us to deliver outsized impact.

AI-centric healthcare platform initiatives.

AI-centric healthcare platform initiatives.

A Cambridge, MA, based global healthcare platform synergizing biotech, medical devices, and AI.

Vyome Holdings, Inc.
Nasdaq: HIND

PRINCIPAL OFFICE

Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138

PHONE

+1 973-832-8147

SUBSIDIARIES

⁠Vyome Therapeutics, Inc.

OFFICE

Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138

Vyome Therapeutics Limited, Subsidiary of Vyome Therapeutics, Inc.

OFFICE

Plot No. 465, Ground Floor, F.I.E., Patparganj Industrial Area, Delhi, India- 110092.

PHONE

+91-99682-17333

*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.

Home

ABOUT

Management

Board Members

Company Vision

Advisory Board

SCIENCE & PIPELINE

Pipeline

Publications

INVESTORS

Investor Home

Quarterly Results

Committees

News & Media

Contact

Vyome Holdings, Inc.
Nasdaq: HIND

PRINCIPAL OFFICE

Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138

PHONE

+1 973-832-8147

SUBSIDIARIES

⁠Vyome Therapeutics, Inc.

OFFICE

Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138

Vyome Therapeutics Limited, Subsidiary of Vyome Therapeutics, Inc.

OFFICE

Plot No. 465, Ground Floor, F.I.E., Patparganj Industrial Area, Delhi, India- 110092.

PHONE

+91-99682-17333

*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.

Home

ABOUT

Management

Board Members

Company Vision

Advisory Board

SCIENCE & PIPELINE

Pipeline

Publications

INVESTORS

Investor Home

Quarterly Results

Committees

News & Media

Contact

A Cambridge, MA, based global healthcare platform synergizing biotech, medical devices, and AI.

Vyome Holdings, Inc.
Nasdaq: HIND

PRINCIPAL OFFICE

Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138

PHONE

+1 973-832-8147

SUBSIDIARIES

⁠Vyome Therapeutics, Inc.

OFFICE

Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138

Vyome Therapeutics Limited, Subsidiary of Vyome Therapeutics, Inc.

OFFICE

Plot No. 465, Ground Floor, F.I.E., Patparganj Industrial Area, Delhi, India- 110092.

PHONE

+91-99682-17333

*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.

Home

ABOUT

Management

Board Members

Company Vision

Advisory Board

SCIENCE & PIPELINE

Pipeline

Publications

INVESTORS

Investor Home

Quarterly Results

Committees

News & Media

Contact